CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;

CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169.

CFI-400437 is potent against PLK4 (IC50 = 0.6 nM) and selective against other members of the PLK family (>10 uM).

CFI-401980 is a potent, selective, novel class TTK (Tyrosine Threonine Kinase) inhibitor with Ki of 0.8 nM, HCT116 GI50 of 13 nM.

CFM-2 is a selective non-competitive AMPAR antagonist.

CFM-4.16 is a CARP-1 functional mimetic (CFM) compound bind with CARP-1, stimulates CARP-1 expression and apoptosis.

c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice..

CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells.

CG-806 (CG806, CG'806) is a novel potent, pan-FLT3/BTK multi-kinase inhibitor with impressive inhibition of leukemic cell proliferation with IC50 at sub-nanomolar or low nanomolar levels.

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.

CGP 52432 is a potent, selective GABAB receptor antagonist (IC50 = 85 nM).

CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 (IC50 = 2.2 μM) with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

CGP 71683A is a potent and highly selective non-peptide antagonist of the NPY Y(5) receptor in the study of obesity.

CGP37849 is a potent, selective and competitive NMDA receptor antagonist (Ki = 35 nM). Anticonvulsive following oral administration in vivo.

CGP-42112 (CGP42112A) is a highly potent, selective Angiotensin-II subtype 2 receptor(AT2 receptor) agonist with Ki of 0.24 nM.

CGP-53353 (DAPH-7) is a selective inhibitor of PKCβII with IC50 of 0.41 uM, shows weak activity on PKCβI with IC50 of 3.8 uM.

CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM.

CGS 21680 hydrochloride is an A2A adenosine receptor agonist (Ki = 27 nM).

CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM.

CGS 27023A (MMI 270) is a potent, orally active MMP inhibitor with Ki of 8-43 nM for MMP1/2/3/9.

CH-223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor.

Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer.

CH5132799 selectively inhibits class I PI3Ks, such as PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ with IC50 values of 0.014, 0.12, 0.50, and 0.36 uM, respectively; shows less inhibition of class II PI3Ks, class III PI3ks, and mTOR.

CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

CH5447240 is a novel potent, selective, orally active hPTHR1 agonist with EC20 of 3.0 nM and EC50 of 12 nM.

CH7057288 (CH-7057288) is a novel potent and selective pan-TRK inhibitor with IC50 of 1.1/7.8/5.1 nM for TRKA/TRKB/TRKC, respectively.

Chaetocin is a potent, specific, SAM-competitive inhibitor of histone H3K9 methyltransferase (HMT) SU(VAR)3-9 with IC50 of 0.6 uM, no actiivty against H4 Lys20-specific HMT PRSET7 and SET7/9.

Chaetominine , an alkaloidal metabolite with a new framework, was characterized from the solid-substrate culture of Chaetomium sp.

CHDI-390576 (CHDI390576) is a potent, cell permeable and CNS penetrant class IIa HDAC inhibitor with IC50 of 54/60/31/50 nM for HDAC4/5/7/9, respectively.

Chelerythrine is a potent, cell permeable inhibitor of protein kinase C (IC50 = 660 nM) that does not inhibit tyrosine protein kinases, cAMP-dependent protein kinase, or calcium/calmodulin-dependent protein kinase.

Chelerythrine is a well-known protein kinase C inhibitor, can inhibit telomerase activity, it also can block the human P2X 7 receptor.

Chelidonic acid is a component of Chelidonium majus L., used as a mild analgesic, an antimicrobial, an acentral nervous system sedative. Chelidonic acid also shows anti-inflammatory activity. Chelidonic acid has potential to inhibit IL-6 production by blo

CHEMBL333994 is a potent and orally effective Cholecystokinin A (CCK-A) antagonist, with an IC50 of 0.67 nM.

Chemocoxib A is a highly potent, selective, cytotoxic COX-2 inhibitor with IC50 of 290 nM and 90 nM for wt mCOX-2 and R120Q COX-2 mutant respectively.

Chetomin (NSC 289491) is a natural product isolated from Chaetomium species which shows antibacterial and antifungal properties, disrupts the interaction of HIF-1α/p300 at low nanomolar concentrations, strongly increases retinal pigment epithelial cells d

Chidamide is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM).

Chiglitazar (CS-038, CS038) is a potent, dual PPARα/γ dual agonist with EC50 of 1.2, 0.08, 1.7 uM for PPARα, PPARγ and PPARδ, respectively.

CHIR-090 is a potent LpxC inhibitor, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin or tobramycin.

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.

CHIR-99021 HCl is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.

CHIR-99021 is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.

CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM

Chlorambucil(WR-139013; CB-1348) is a chemotherapy drug that has been mainly used in the treatment of chronic lymphocytic leukemia.

Chloramphenicol (Chloromycetin)

Chlorantraniliprole is an insecticide that potently and selectively activates insect ryanodine receptor, with EC50s of 40 nM and 50 nM for Drosophila melanogaster and H. virescens ryanodine receptor, and ∼300-fold more potent than that in the mouse myobla

Chlorhexidine hydrochloride is an antiseptic effective against a wide variety of gram-negative and gram-positive organisms.

Chlormezanone (Trancopal)

Chloroquine diphosphate is an antimalarial drug and autophagy/lysosome inhibitor; inhibits Toll-like receptor (TLR) signalling in plasmacytoid dendritic cells (pDCs).

Chlorothiazide

Chlorpheniramine maleate is an histamine H1 receptor antagonist with IC50 of 12 nM.

Chlorpromazine Hydrochloride is a dopamine and potassium channel inhibitor used as the prototypical phenothiazine antipsychotic drug.

Chlorprothixene has strong binding affinities to dopamine and histamine receptors, such as D1, D2, D3, D5, H1, 5-HT2, 5-HT6 and 5-HT7, with Ki of 18 nM, 2.96 nM, 4.56 nM, 9 nM, 3.75 nM, 9.4 nM, 3 nM and 5.6 nM, respectively.

Chlortalidone is a diuretic drug used to treat hypertension.

Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.Chlorzoxazone is currently being used as a marker substrate in vitro/vivo studies to qua

CHMFL-ABL-053 is a potent, selective and orally available Bcr-Abl/Src/p38 kinase inhibitor with IC50 of 70/62/90 nM.

CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.

CHMFL-KIT-031 is a highly selective KIT kinase primary V559D mutant inhibitor with IC50/Kd of 28/266 nM, 10-20 fold selectivity over KIT wt.

CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3

Cholestenone is the intermediate oxidation product of cholesterol.

Choline fenofibrate is a newly developed choline salt of fenofibric acid, a synthetic phenoxy-isobutyric acid derivate with antihyperlipidemic activity that acts as an PPARα agonist.

CHR-2797 is an aminopeptidase inhibitor, with IC50 values of 100 nM for LAP3 (LAP), 150 nM for PSAP (PuSA) and 220 nM for CD13 (Aminopeptidase N).

CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.

CHR-6494 is a potent and selective Haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase) inhibitor that blocks H3T3ph phosphorylation.

CHS-828 is a pyridyl cyanoguanidine anti-tumor agent that has been identified as a competitive inhibitor of Nampt as well as an inhibitor of NF-κB pathway activity.

ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

CI-1040 (PD 184352) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM.

CI-1044 is a potent, selective and orally bioavailable PDE4 inhibitor with IC50 of 0.27 uM, displays high selectivity for PDE4 versus PDE1/3/5, and no PDE4 subtype (4A-D) selectivities.

CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.

CI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively.

CI-976 (PD 128042) is a potent, selective, orally bioavailable inhibitor of ACAT-1 (Acetyl-CoA acetyltransferase 1) with IC50 of 73 nM.

CI994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM.

cIAP1 E3 ligase inhibitor D19 (cIAP1 inhibitor D19) is a small-molecule inhibitor of E3 ligase activity of cIAP1, inhibits cIAP1 auto-ubiquitination with IC50 of 14.1 uM, shows no effect on autoubiquitination of BRCA1/BARD1.

cIAP1 E3 ligase inhibitor D19-14 (cIAP1 inhibitor D19-14) is an improved analog of D19, demonstrates significantly increased ability to inhibit cIAP1 autoubiquitination and reduce protein levels of c-MYC in vitro.

Ciclesonide(RPR251526) is a glucocorticoid used to treat obstructive airway diseases.

Ciclopirox (Penlac)

CID 1375606 is a surrogate agonist of orphan G protein-coupled receptor GPR27.

CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM.

CID 9998128 is a potential multi-target drug for the Alzheimer's disease (AD), inhibits the Aβ42 amyloid fibrillization and is capable to clear Aβ42 fibrils.

CID-1067700 is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.

CID-2011756 is a cell-active ATP competitive and specific PKD1 inhibitor that inhibits phorbol ester-induced endogenous PKD1 activation in LNCaP prostate cancer cells.

CID-2858522 is a selectively inhibits protein kinase C (PKC)-induced activation of the NF-κB pathway (IC50 < 0.1 μM for PMA-stimulated IL-8 production).

CID3528206 is a potent, small molecule yeast TORC1 inhibitor that inhibits TORC1 activity both in vitro and in vivo with IC50 of 150 nM and 3.9 uM, respectively.

CID5721353 is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor).

CID755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM; exhibits selective PKD1 inhibition when compared with AKT, PLK1, CAK, CAMKIIα, and PKC isoforms.

CID-797718 is a compound with unknown details.

CID888706 is a small molecule, pan activator of Rho-family GTPases..

CIDD 0067106 is a novel natural product-based diaryloxazole that potent and selective antiproliferative activities against androgen receptor-positive breast cancer cells (MDA-MB-453 cell GI50=0.8 uM).

Cidofovir(Vistide)

CIL56 is a small molecule that induces cellular ferroptosis through production of iron-dependent reactive oxygen species (ROS).

Cilastatin is an inhibitor of dipeptidase (dehydropeptidase I), a renal dipeptidase.

Cilastazol is a 2-oxo-quinoline with vasodilator, antimitogenic, antithrombotic, and cardiotonic properties. This compound has been shown to cause inhibition of adenosine uptake, eventually resulting in changes to cAMP levels. Studies have shown Cilostazo

Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Ciliobrevin A(HPI-4) is a Hedgehog pathway inhibitor and ciliogenesis inhibitor.

Ciliobrevin D is a cell-permeable, reversible, specific inhibitor of cytoplasmic dynein, blocks dynein-dependent microtubule gliding and ATPase activity while sparing kinesin dependent cellular trafficking.

Cilnidipine(FRC8653) is a dual L- and N-type calcium channel blocker and displays antihypertensive, sympatholytic and neuroprotective activity.

Cilofexor (GS-9674, GS9674) is novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.

Cilomilast(SB 207499; Ariflo) is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity.

Ciluprevir (BILN2061) is a potent HCV NS3/4A protease inhibitor with Ki of 0.66 and 0.30 nM for NS3-NS4A protease of HCV 1b and HCV 1a, respectively.

Cimetidine is a histamine-2 (H2) receptor antagonist.

Cimiside B, a glycoside alkaloid, isolated from the rhizome of Cimicifuga dahurica.

Cinacalcet(AMG-073) is an orally active, second-generation calcimimetic compound; AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism.

Cinaciguat is an activator of sGC that binds to a regulatory site, resulting in activation in an NO-independent manner (Kd = 3.2 nM).

Cinchonine is a natural compound present in Cinchona bark. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells.

Cinepazide Maleate is a vasodilator.

Cinnarizine is a medication derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker.

Cinobufotalin is a steroid glycoside originally isolated from the Asiatic toad (B. gargarizans) and has diverse biological activities.

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.

Cipemastat (Ro 32-3555) is a potent, second-generation, orally active MMP inhibitor, preferentially inhibits collagenases (MMP-1, -8, and -13) and gelatinase B (MMP-9).

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

Ciproxifan is an antagonists of H3-type histamine receptors.

Ciproxifan maleate(FUB-359 maleate) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

CIQ is a positive allosteric modulator selective for NR2C/D containing NMDA receptors (EC50 = 2.7 and 2.8 µM for NR2C and NR2D, respectively).

Ciraparantag(PER977) is an intravenously administered anticoagulant Reversal Agent.

Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors, with antidepressant, anxiolytic and antinociceptive activities.

cis Ned-19 is the stereoisomer of trans Ned-19, a chemical probe for the Ca(2+)-releasing second messenger NAADP.

Cisapride is a SR-4 agonist also known as Enteropride

Cisatracurium Besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.

Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.

Citalopram hydrobromide is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. It has US FDA approval to treat major depression.

Citarinostat(ACY-241) is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.

Citicoline Sodium

CJ-13610 is a potent 5-Lipoxygenase (5-LO) inhibitor that suppresses 5-LO product formation with IC50 of 70 nM.

CK 666 (CK 0944666) is a small molecule Arp2/3 complex inhibitor with IC50 of 4 uM, inhibits actin polymerization with either BtArp2/3 complex (IC50=17 uM) or SpArp2/3 complex (IC50=5 uM).

CK1-IN-3c is a novel casein kinase 1δ/ε (CK1δ/ε) inhibitor with IC50 of 1.6 uM.

CK-2127107(CK-107, Reldesemtiv) is a novel orally active fast skeletal troponin activator, selectively activates fast skeletal myofibrils with EC50 of 3.4 uM.

CK2-IN-1 is a potent, competitive inhibitor of ATP binding to Casein kinase 2(CK2) with IC50 of 9 nM, induces differentiation of epidermal progenitor cells to terminally differentiated keratinocytes with EC50 of 0.1 uM..

CK-636(CK-0944636) is a small molecule inhibitor of Arp2/3 complex; Inhibitor of actin polymerization; Cell permeable inhibitor of human (IC50=4μM), fission yeast (IC50=24μM) and bovine (IC50=32μM) Arp2/3 complex between Arp2 and Arp3.

CK-869 is an inhibitor of human and bovine actin-related protein 2/3 (Arp2/3) complex.

CKD-516 (Valecobulin, CKD516) is a potent beta-tubulin polymerization inhibitor with marked antitumor activity both in vitro and in vivo.

CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.

CL 316243 (BTA 243) is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM.

CL 316243 is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM.

CL27c is a cell-permeable, inhaled lipophilic ester prodrug of CL27e, which is a potent, selective pan-class I PI3K inhibitor, CL27c is inactive in PI3K enzymatic assay, once inside the cytoplasm, CL27c is metabolized by unspecific esterases into CL27e.

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level.

CL-82198 is a potent, selective inhibitor of MMP-13 (89% inhibition at 10 ug/mL), displays no activity at MMP-1, MMP-9 and TACE, significantly reduces the migration of LS174 cells by 55% at 10 uM..

Cladribine (Leustatin, Litak, 2CDA) is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50 of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively.

Cl-amidine (hydrochloride) is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9 μM for PAD4.

Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays.

Clanfenur is a substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity.

Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor.

Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma..

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.

Clevidipine(Clevidipine) is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.

Clevudine (Levovir) is an antiviral drug for the treatment of hepatitis B,showed potent activity against COVID-19(SARS-COV-2) .

Clindamycin HCl (Dalacin)

Clindamycin phosphate

Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.

Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities.

CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively.

CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

Clobetasol propionate

Clocapramine hydrochloride hydrate is an antagonist of the D2 and 5-HT2A receptors.

Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It

Clofazimine is a fat-soluble iminophenazine dye, has a marked anti-inflammatory effect, has been used in combination with other antimycobacterial drugs to treat AIDS and Crohn's disease.

Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females.

Clomifene Citrate is a selective estrogen receptor modulator.

Clomipramine HCl is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively.

Clonidine Hydrochloride is a centrally acting alpha-agonist hypotensive agent.

Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent.

Clopidogrel is an irreversible inhibitor of the P2Y12 receptor, which is responsible for initiating signal transduction via a GPCR. The signal cascade initiates platelet aggregation and thus clopidogrel has the effect of “thinning” the blood.

Cloprostenol Sodium is a synthetic F series prostaglandin that functions as a potent agonist towards the PGF2αR (FP receptor). It is known that Cloprostenol Sodium is less selective than other agonists such as fluprostenol, however it displays more potenc

Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae).

Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro.

Clozapine(HF 1854) is a 5-HT2A/2C and dopamine receptor blocker with Ki values of 21, 170, 170, 230 and 330 nM for D4, D3, D1, D2 and D5 receptors respectively.

CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior.

ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay.

CLR1501 is a synthetic analogs of the tumor-targeting agent alkylphosphocholine (APC), which is specifically attracted to cancer cells.

CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM).

CM-272 is a first-in-class reversible dual small molecule inhibitor against G9a and DNMTs in hematological malignancies.

CM-346 increased the power of the low-frequency θ-rhythm (4.8–5.8 Hz) and the dominant activity peak (6.0–7.2 Hz) and decreased the spectral power in the 19–20 Hz band.

CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively.

CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM).

CMC·HCI

CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo.

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

CMK is a RSK2 kinase inhibitor.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMP8 is a high-affinity ligand that binds only to mutant ERLBD.

CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM)..

CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays.

CMX001 (Brincidofovir; HDP-CDV) was developed as an orally active, lipophilic form of cidofovir (CDV); has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses and orthopoxviruses.IC50 Value: 5.5 nM (EC50, in PDA at 7 dpi) [3]Target: anti-CMVCMX001 is currently in Phase II clinical studies for development as a therapeutic agent for human CMV, adenovirus and BK virus infections, as well as, for adverse events following smallpox vaccinations.in vitro: In PDA at 7 dpi, the CMX001 50% effective concentration (EC50) was 5.55 nM, the 50% cytotoxic concentration (CC50) was 184.6 nM, and the 50% selectivity index (SI50) was 33.3. The EC90 was 19.7 nM, the CC90 was 5,054 nM, and the SI90 was 256.1. In COS-7 cells, JCV replication was faster and the EC50 and EC90 were 18- and 37-fold higher than those in PDA, i.e., 0.1 μM and 0.74 μM (CC50, 0.67 μM; SI50, 6.7; CC90, 12.2 μM; SI90, 16.5) at 5 dpi [3].in vivo: CMX001 and CDV are equally efficacious at protecting mice from mortality following high ectromelia virus doses (10,000 x LD(50)) introduced by the intra-nasal route or small particle aerosol. Using CMX001 at a 10mg/kg dose followed by 2.5mg/kg doses every other-day for 14 days provided solid protection against mortality and weight loss following an intra-nasal challenge of (100-200) x LD(50) of ectromelia virus [1]. When CMX001 was administered orally to mice infected with HSV-1, mortality was reduced significantly (p≤0.001) with all three dose levels when treatments were initiated 24 h post viral inoculation. When treatments were started 48 h post viral inoculation, 5 and 2.5 mg/kg significantly reduced mortality (p≤ 0.001). If treatments were delayed until 72 h post viral inoculation, CMX001 did not reduce mortality or increase the mean day to death. When mice were infected intranasally with HSV-1 and treatments initiated 24 h post viral inoculation using CMX001 at 5 mg/kg or ACV at 100 mg/kg, virus replication in target organs was reduced by both CMX001 and ACV when compared to vehicle treated mice [2]. Toxicity: Diarrhea was the most common adverse event in patients receiving CMX001 at doses of 200 mg weekly or higher and was dose-limiting at 200 mg twice weekly. Myelosuppression and nephrotoxicity were not observed [4].

CN427 (CN-427) is novel BRD4 (BD1, 2) inhibitor with IC50 of 66 nM, MV4-11 viability IC50 of 1.1 uM..

CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.

CNDAC (DFP-10917; TAS-109) is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity.

CNDAC is the active component of sapacitabine.

CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU).

CNQX is a potent AMPA/kainate receptor antagonist. Also antagonist at glycine modulatory site on NMDA receptor complex.